Israeli Health Ministry Tests AI Systems for Autonomous Medical Decisions

The Israeli Ministry of Health and the Innovation Authority have launched a pioneering regulatory sandbox to test highly autonomous artificial intelligence (AI) systems in medical settings. This experimental framework allows three selected Israeli companies to pilot AI technologies in hospitals under strict supervision, aiming to evaluate their accuracy, patient safety, effectiveness, and potential risks before formal regulatory approval is established.

The three companies, Pulsenmore, Cardio Medical, and Simahoc, are exploring different AI applications, including home ultrasound analysis without physician interpretation, remote monitoring of heart failure patients using voice and wearable data, and real-time AI guidance during fetal weight ultrasound scans. These pilots mark a significant shift from AI systems that merely assist doctors to those capable of making independent clinical decisions, such as determining if an ultrasound is normal or requires urgent follow-up.

For example, Pulsenmore’s AI will analyze home ultrasound images to decide if further medical evaluation is needed without a doctor’s review. Cardio Medical’s system integrates patient voice, questionnaire responses, smartphone, smartwatch, and medical record data to detect early signs of heart failure deterioration and may recommend medication adjustments per pre-set protocols. Simahoc’s AI will guide ultrasound operators in real time to capture precise fetal measurements, potentially enabling less specialized staff to perform these scans and improving access in underserved areas.

The pilots will also address complex regulatory questions, such as when AI can act autonomously, when physician oversight is required, and liability issues if AI recommendations cause harm. The Ministry of Health and Innovation Authority will use the data collected to define necessary approvals, restrictions, and controls for broader community use. This initiative aims to accelerate AI integration in healthcare while managing risks associated with increased system independence.

Alongside regulatory support, the companies will receive funding from the Innovation Authority’s pilot fund. The outcomes will not only shape Israeli healthcare AI policy but also assist these firms in navigating international regulatory environments.